Peter Stopfer

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 344 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

F. Eskens, Constantijne H. Mom, André Planting et al. · British Journal of Cancer · 2007 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling et al. · Clinical Cancer Research · 2009 · 169 citations

Medicine, Oncology, Pharmacology +16

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Martin Reck, R. Kaiser, C. Eschbach et al. · Annals of Oncology · 2011 · 149 citations · Full text

Medicine, Oncology, Pharmacology +9

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Peter Stopfer, Kristell Marzin, H. Narjes et al. · Cancer Chemotherapy and Pharmacology · 2011 · 134 citations

Pharmacy, Pharmacokinetics, Pharmacology +7